nodes	percent_of_prediction	percent_of_DWPC	metapath
Zuclopenthixol—Glycosuria—Doxorubicin—thyroid cancer	0.00319	0.00338	CcSEcCtD
Zuclopenthixol—Amenorrhoea—Epirubicin—thyroid cancer	0.00318	0.00337	CcSEcCtD
Zuclopenthixol—Abdominal pain—Vandetanib—thyroid cancer	0.00316	0.00335	CcSEcCtD
Zuclopenthixol—Body temperature increased—Vandetanib—thyroid cancer	0.00316	0.00335	CcSEcCtD
Zuclopenthixol—Skin discolouration—Epirubicin—thyroid cancer	0.0031	0.00328	CcSEcCtD
Zuclopenthixol—Dyskinesia—Epirubicin—thyroid cancer	0.00298	0.00315	CcSEcCtD
Zuclopenthixol—Syncope—Sorafenib—thyroid cancer	0.00297	0.00314	CcSEcCtD
Zuclopenthixol—Leukopenia—Sorafenib—thyroid cancer	0.00296	0.00313	CcSEcCtD
Zuclopenthixol—Blood bilirubin increased—Epirubicin—thyroid cancer	0.00296	0.00313	CcSEcCtD
Zuclopenthixol—Amenorrhoea—Doxorubicin—thyroid cancer	0.00294	0.00312	CcSEcCtD
Zuclopenthixol—Loss of consciousness—Sorafenib—thyroid cancer	0.00291	0.00308	CcSEcCtD
Zuclopenthixol—Asthenia—Vandetanib—thyroid cancer	0.00287	0.00304	CcSEcCtD
Zuclopenthixol—Gait disturbance—Epirubicin—thyroid cancer	0.00286	0.00303	CcSEcCtD
Zuclopenthixol—Skin discolouration—Doxorubicin—thyroid cancer	0.00286	0.00303	CcSEcCtD
Zuclopenthixol—Hypertension—Sorafenib—thyroid cancer	0.00286	0.00302	CcSEcCtD
Zuclopenthixol—Pruritus—Vandetanib—thyroid cancer	0.00283	0.003	CcSEcCtD
Zuclopenthixol—Myalgia—Sorafenib—thyroid cancer	0.00282	0.00298	CcSEcCtD
Zuclopenthixol—Unspecified disorder of skin and subcutaneous tissue—Sorafenib—thyroid cancer	0.0028	0.00296	CcSEcCtD
Zuclopenthixol—Ventricular tachycardia—Epirubicin—thyroid cancer	0.0028	0.00296	CcSEcCtD
Zuclopenthixol—Injection site reaction—Epirubicin—thyroid cancer	0.00278	0.00294	CcSEcCtD
Zuclopenthixol—Abnormal dreams—Epirubicin—thyroid cancer	0.00276	0.00292	CcSEcCtD
Zuclopenthixol—Dry mouth—Sorafenib—thyroid cancer	0.00275	0.00291	CcSEcCtD
Zuclopenthixol—Dyskinesia—Doxorubicin—thyroid cancer	0.00275	0.00291	CcSEcCtD
Zuclopenthixol—Diarrhoea—Vandetanib—thyroid cancer	0.00274	0.0029	CcSEcCtD
Zuclopenthixol—Blood bilirubin increased—Doxorubicin—thyroid cancer	0.00274	0.0029	CcSEcCtD
Zuclopenthixol—Salivary hypersecretion—Epirubicin—thyroid cancer	0.00272	0.00287	CcSEcCtD
Zuclopenthixol—Anaphylactic shock—Sorafenib—thyroid cancer	0.0027	0.00286	CcSEcCtD
Zuclopenthixol—Shock—Sorafenib—thyroid cancer	0.00266	0.00281	CcSEcCtD
Zuclopenthixol—Gait disturbance—Doxorubicin—thyroid cancer	0.00265	0.00281	CcSEcCtD
Zuclopenthixol—Nervous system disorder—Sorafenib—thyroid cancer	0.00265	0.0028	CcSEcCtD
Zuclopenthixol—Dizziness—Vandetanib—thyroid cancer	0.00265	0.0028	CcSEcCtD
Zuclopenthixol—Thrombocytopenia—Sorafenib—thyroid cancer	0.00264	0.0028	CcSEcCtD
Zuclopenthixol—Skin disorder—Sorafenib—thyroid cancer	0.00262	0.00278	CcSEcCtD
Zuclopenthixol—Ventricular tachycardia—Doxorubicin—thyroid cancer	0.00259	0.00274	CcSEcCtD
Zuclopenthixol—Anorexia—Sorafenib—thyroid cancer	0.00257	0.00272	CcSEcCtD
Zuclopenthixol—Injection site reaction—Doxorubicin—thyroid cancer	0.00257	0.00272	CcSEcCtD
Zuclopenthixol—Abnormal dreams—Doxorubicin—thyroid cancer	0.00256	0.00271	CcSEcCtD
Zuclopenthixol—Vomiting—Vandetanib—thyroid cancer	0.00254	0.00269	CcSEcCtD
Zuclopenthixol—Rash—Vandetanib—thyroid cancer	0.00252	0.00267	CcSEcCtD
Zuclopenthixol—Dermatitis—Vandetanib—thyroid cancer	0.00252	0.00267	CcSEcCtD
Zuclopenthixol—Salivary hypersecretion—Doxorubicin—thyroid cancer	0.00251	0.00266	CcSEcCtD
Zuclopenthixol—Headache—Vandetanib—thyroid cancer	0.00251	0.00265	CcSEcCtD
Zuclopenthixol—Musculoskeletal discomfort—Sorafenib—thyroid cancer	0.00246	0.0026	CcSEcCtD
Zuclopenthixol—Hypertonia—Epirubicin—thyroid cancer	0.00245	0.00259	CcSEcCtD
Zuclopenthixol—Abnormal vision—Epirubicin—thyroid cancer	0.00244	0.00258	CcSEcCtD
Zuclopenthixol—Dyspnoea—Sorafenib—thyroid cancer	0.00241	0.00255	CcSEcCtD
Zuclopenthixol—Nausea—Vandetanib—thyroid cancer	0.00238	0.00252	CcSEcCtD
Zuclopenthixol—Dyspepsia—Sorafenib—thyroid cancer	0.00238	0.00251	CcSEcCtD
Zuclopenthixol—Decreased appetite—Sorafenib—thyroid cancer	0.00235	0.00248	CcSEcCtD
Zuclopenthixol—Gastrointestinal disorder—Sorafenib—thyroid cancer	0.00233	0.00247	CcSEcCtD
Zuclopenthixol—Fatigue—Sorafenib—thyroid cancer	0.00233	0.00246	CcSEcCtD
Zuclopenthixol—Pain—Sorafenib—thyroid cancer	0.00231	0.00244	CcSEcCtD
Zuclopenthixol—Constipation—Sorafenib—thyroid cancer	0.00231	0.00244	CcSEcCtD
Zuclopenthixol—Vascular purpura—Epirubicin—thyroid cancer	0.00227	0.0024	CcSEcCtD
Zuclopenthixol—Hypertonia—Doxorubicin—thyroid cancer	0.00227	0.0024	CcSEcCtD
Zuclopenthixol—Abnormal vision—Doxorubicin—thyroid cancer	0.00226	0.00239	CcSEcCtD
Zuclopenthixol—Gastrointestinal pain—Sorafenib—thyroid cancer	0.00221	0.00234	CcSEcCtD
Zuclopenthixol—Hot flush—Epirubicin—thyroid cancer	0.00217	0.0023	CcSEcCtD
Zuclopenthixol—Increased appetite—Epirubicin—thyroid cancer	0.00216	0.00229	CcSEcCtD
Zuclopenthixol—Menopausal symptoms—Epirubicin—thyroid cancer	0.00215	0.00228	CcSEcCtD
Zuclopenthixol—Body temperature increased—Sorafenib—thyroid cancer	0.00213	0.00226	CcSEcCtD
Zuclopenthixol—Abdominal pain—Sorafenib—thyroid cancer	0.00213	0.00226	CcSEcCtD
Zuclopenthixol—Purpura—Epirubicin—thyroid cancer	0.00211	0.00223	CcSEcCtD
Zuclopenthixol—Vascular purpura—Doxorubicin—thyroid cancer	0.0021	0.00222	CcSEcCtD
Zuclopenthixol—Hot flush—Doxorubicin—thyroid cancer	0.00201	0.00212	CcSEcCtD
Zuclopenthixol—Increased appetite—Doxorubicin—thyroid cancer	0.002	0.00212	CcSEcCtD
Zuclopenthixol—Migraine—Epirubicin—thyroid cancer	0.002	0.00211	CcSEcCtD
Zuclopenthixol—Menopausal symptoms—Doxorubicin—thyroid cancer	0.00199	0.00211	CcSEcCtD
Zuclopenthixol—Hypersensitivity—Sorafenib—thyroid cancer	0.00199	0.0021	CcSEcCtD
Zuclopenthixol—Purpura—Doxorubicin—thyroid cancer	0.00195	0.00206	CcSEcCtD
Zuclopenthixol—Asthenia—Sorafenib—thyroid cancer	0.00194	0.00205	CcSEcCtD
Zuclopenthixol—Pruritus—Sorafenib—thyroid cancer	0.00191	0.00202	CcSEcCtD
Zuclopenthixol—Ataxia—Epirubicin—thyroid cancer	0.00191	0.00202	CcSEcCtD
Zuclopenthixol—Liver function test abnormal—Epirubicin—thyroid cancer	0.00187	0.00198	CcSEcCtD
Zuclopenthixol—Migraine—Doxorubicin—thyroid cancer	0.00185	0.00196	CcSEcCtD
Zuclopenthixol—Diarrhoea—Sorafenib—thyroid cancer	0.00185	0.00195	CcSEcCtD
Zuclopenthixol—Breast disorder—Epirubicin—thyroid cancer	0.00183	0.00194	CcSEcCtD
Zuclopenthixol—Nasopharyngitis—Epirubicin—thyroid cancer	0.00181	0.00192	CcSEcCtD
Zuclopenthixol—Alanine aminotransferase increased—Epirubicin—thyroid cancer	0.00179	0.00189	CcSEcCtD
Zuclopenthixol—Dizziness—Sorafenib—thyroid cancer	0.00178	0.00189	CcSEcCtD
Zuclopenthixol—Ataxia—Doxorubicin—thyroid cancer	0.00177	0.00187	CcSEcCtD
Zuclopenthixol—Eosinophilia—Epirubicin—thyroid cancer	0.00174	0.00184	CcSEcCtD
Zuclopenthixol—Liver function test abnormal—Doxorubicin—thyroid cancer	0.00173	0.00184	CcSEcCtD
Zuclopenthixol—Vomiting—Sorafenib—thyroid cancer	0.00172	0.00182	CcSEcCtD
Zuclopenthixol—Rash—Sorafenib—thyroid cancer	0.0017	0.0018	CcSEcCtD
Zuclopenthixol—Dermatitis—Sorafenib—thyroid cancer	0.0017	0.0018	CcSEcCtD
Zuclopenthixol—Breast disorder—Doxorubicin—thyroid cancer	0.0017	0.0018	CcSEcCtD
Zuclopenthixol—Headache—Sorafenib—thyroid cancer	0.00169	0.00179	CcSEcCtD
Zuclopenthixol—Nasopharyngitis—Doxorubicin—thyroid cancer	0.00168	0.00178	CcSEcCtD
Zuclopenthixol—Pancytopenia—Epirubicin—thyroid cancer	0.00167	0.00176	CcSEcCtD
Zuclopenthixol—Alanine aminotransferase increased—Doxorubicin—thyroid cancer	0.00166	0.00175	CcSEcCtD
Zuclopenthixol—Neutropenia—Epirubicin—thyroid cancer	0.00164	0.00174	CcSEcCtD
Zuclopenthixol—Dysuria—Epirubicin—thyroid cancer	0.00164	0.00174	CcSEcCtD
Zuclopenthixol—Eosinophilia—Doxorubicin—thyroid cancer	0.00161	0.0017	CcSEcCtD
Zuclopenthixol—Nausea—Sorafenib—thyroid cancer	0.0016	0.0017	CcSEcCtD
Zuclopenthixol—Photosensitivity reaction—Epirubicin—thyroid cancer	0.0016	0.00169	CcSEcCtD
Zuclopenthixol—Weight increased—Epirubicin—thyroid cancer	0.0016	0.00169	CcSEcCtD
Zuclopenthixol—Weight decreased—Epirubicin—thyroid cancer	0.00159	0.00168	CcSEcCtD
Zuclopenthixol—Hyperglycaemia—Epirubicin—thyroid cancer	0.00158	0.00167	CcSEcCtD
Zuclopenthixol—Drowsiness—Epirubicin—thyroid cancer	0.00156	0.00166	CcSEcCtD
Zuclopenthixol—Pancytopenia—Doxorubicin—thyroid cancer	0.00154	0.00163	CcSEcCtD
Zuclopenthixol—Jaundice—Epirubicin—thyroid cancer	0.00152	0.00161	CcSEcCtD
Zuclopenthixol—Dysuria—Doxorubicin—thyroid cancer	0.00152	0.00161	CcSEcCtD
Zuclopenthixol—Neutropenia—Doxorubicin—thyroid cancer	0.00152	0.00161	CcSEcCtD
Zuclopenthixol—Sweating—Epirubicin—thyroid cancer	0.0015	0.00159	CcSEcCtD
Zuclopenthixol—Photosensitivity reaction—Doxorubicin—thyroid cancer	0.00148	0.00157	CcSEcCtD
Zuclopenthixol—Hepatobiliary disease—Epirubicin—thyroid cancer	0.00148	0.00157	CcSEcCtD
Zuclopenthixol—Weight increased—Doxorubicin—thyroid cancer	0.00148	0.00156	CcSEcCtD
Zuclopenthixol—Weight decreased—Doxorubicin—thyroid cancer	0.00147	0.00155	CcSEcCtD
Zuclopenthixol—Hyperglycaemia—Doxorubicin—thyroid cancer	0.00146	0.00155	CcSEcCtD
Zuclopenthixol—Agranulocytosis—Epirubicin—thyroid cancer	0.00146	0.00154	CcSEcCtD
Zuclopenthixol—Drowsiness—Doxorubicin—thyroid cancer	0.00145	0.00153	CcSEcCtD
Zuclopenthixol—Jaundice—Doxorubicin—thyroid cancer	0.00141	0.00149	CcSEcCtD
Zuclopenthixol—Sweating—Doxorubicin—thyroid cancer	0.00139	0.00147	CcSEcCtD
Zuclopenthixol—Urinary tract disorder—Epirubicin—thyroid cancer	0.00139	0.00147	CcSEcCtD
Zuclopenthixol—Oedema peripheral—Epirubicin—thyroid cancer	0.00138	0.00146	CcSEcCtD
Zuclopenthixol—Connective tissue disorder—Epirubicin—thyroid cancer	0.00138	0.00146	CcSEcCtD
Zuclopenthixol—Urethral disorder—Epirubicin—thyroid cancer	0.00138	0.00146	CcSEcCtD
Zuclopenthixol—Hepatobiliary disease—Doxorubicin—thyroid cancer	0.00137	0.00145	CcSEcCtD
Zuclopenthixol—Visual impairment—Epirubicin—thyroid cancer	0.00135	0.00143	CcSEcCtD
Zuclopenthixol—Agranulocytosis—Doxorubicin—thyroid cancer	0.00135	0.00143	CcSEcCtD
Zuclopenthixol—Eye disorder—Epirubicin—thyroid cancer	0.00131	0.00139	CcSEcCtD
Zuclopenthixol—Tinnitus—Epirubicin—thyroid cancer	0.00131	0.00139	CcSEcCtD
Zuclopenthixol—Cardiac disorder—Epirubicin—thyroid cancer	0.0013	0.00138	CcSEcCtD
Zuclopenthixol—Urinary tract disorder—Doxorubicin—thyroid cancer	0.00128	0.00136	CcSEcCtD
Zuclopenthixol—Oedema peripheral—Doxorubicin—thyroid cancer	0.00128	0.00135	CcSEcCtD
Zuclopenthixol—Connective tissue disorder—Doxorubicin—thyroid cancer	0.00128	0.00135	CcSEcCtD
Zuclopenthixol—Angiopathy—Epirubicin—thyroid cancer	0.00127	0.00135	CcSEcCtD
Zuclopenthixol—Urethral disorder—Doxorubicin—thyroid cancer	0.00127	0.00135	CcSEcCtD
Zuclopenthixol—Immune system disorder—Epirubicin—thyroid cancer	0.00127	0.00134	CcSEcCtD
Zuclopenthixol—Arrhythmia—Epirubicin—thyroid cancer	0.00125	0.00133	CcSEcCtD
Zuclopenthixol—Visual impairment—Doxorubicin—thyroid cancer	0.00125	0.00133	CcSEcCtD
Zuclopenthixol—Mental disorder—Epirubicin—thyroid cancer	0.00123	0.0013	CcSEcCtD
Zuclopenthixol—Malnutrition—Epirubicin—thyroid cancer	0.00122	0.00129	CcSEcCtD
Zuclopenthixol—Erythema—Epirubicin—thyroid cancer	0.00122	0.00129	CcSEcCtD
Zuclopenthixol—Eye disorder—Doxorubicin—thyroid cancer	0.00121	0.00129	CcSEcCtD
Zuclopenthixol—Tinnitus—Doxorubicin—thyroid cancer	0.00121	0.00128	CcSEcCtD
Zuclopenthixol—Cardiac disorder—Doxorubicin—thyroid cancer	0.00121	0.00128	CcSEcCtD
Zuclopenthixol—Flatulence—Epirubicin—thyroid cancer	0.0012	0.00127	CcSEcCtD
Zuclopenthixol—Tension—Epirubicin—thyroid cancer	0.0012	0.00127	CcSEcCtD
Zuclopenthixol—Nervousness—Epirubicin—thyroid cancer	0.00119	0.00126	CcSEcCtD
Zuclopenthixol—Angiopathy—Doxorubicin—thyroid cancer	0.00118	0.00125	CcSEcCtD
Zuclopenthixol—Immune system disorder—Doxorubicin—thyroid cancer	0.00117	0.00124	CcSEcCtD
Zuclopenthixol—Arrhythmia—Doxorubicin—thyroid cancer	0.00116	0.00123	CcSEcCtD
Zuclopenthixol—Vision blurred—Epirubicin—thyroid cancer	0.00115	0.00122	CcSEcCtD
Zuclopenthixol—Mental disorder—Doxorubicin—thyroid cancer	0.00114	0.0012	CcSEcCtD
Zuclopenthixol—Ill-defined disorder—Epirubicin—thyroid cancer	0.00113	0.0012	CcSEcCtD
Zuclopenthixol—Erythema—Doxorubicin—thyroid cancer	0.00113	0.0012	CcSEcCtD
Zuclopenthixol—Malnutrition—Doxorubicin—thyroid cancer	0.00113	0.0012	CcSEcCtD
Zuclopenthixol—Agitation—Epirubicin—thyroid cancer	0.00112	0.00119	CcSEcCtD
Zuclopenthixol—Flatulence—Doxorubicin—thyroid cancer	0.00111	0.00118	CcSEcCtD
Zuclopenthixol—Tension—Doxorubicin—thyroid cancer	0.00111	0.00117	CcSEcCtD
Zuclopenthixol—Malaise—Epirubicin—thyroid cancer	0.0011	0.00117	CcSEcCtD
Zuclopenthixol—Nervousness—Doxorubicin—thyroid cancer	0.0011	0.00116	CcSEcCtD
Zuclopenthixol—Vertigo—Epirubicin—thyroid cancer	0.0011	0.00116	CcSEcCtD
Zuclopenthixol—Syncope—Epirubicin—thyroid cancer	0.0011	0.00116	CcSEcCtD
Zuclopenthixol—Leukopenia—Epirubicin—thyroid cancer	0.00109	0.00116	CcSEcCtD
Zuclopenthixol—Palpitations—Epirubicin—thyroid cancer	0.00108	0.00114	CcSEcCtD
Zuclopenthixol—Loss of consciousness—Epirubicin—thyroid cancer	0.00107	0.00114	CcSEcCtD
Zuclopenthixol—Vision blurred—Doxorubicin—thyroid cancer	0.00107	0.00113	CcSEcCtD
Zuclopenthixol—Convulsion—Epirubicin—thyroid cancer	0.00106	0.00112	CcSEcCtD
Zuclopenthixol—Hypertension—Epirubicin—thyroid cancer	0.00106	0.00112	CcSEcCtD
Zuclopenthixol—Ill-defined disorder—Doxorubicin—thyroid cancer	0.00105	0.00111	CcSEcCtD
Zuclopenthixol—Myalgia—Epirubicin—thyroid cancer	0.00104	0.0011	CcSEcCtD
Zuclopenthixol—Agitation—Doxorubicin—thyroid cancer	0.00104	0.0011	CcSEcCtD
Zuclopenthixol—Anxiety—Epirubicin—thyroid cancer	0.00104	0.0011	CcSEcCtD
Zuclopenthixol—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—thyroid cancer	0.00103	0.00109	CcSEcCtD
Zuclopenthixol—Discomfort—Epirubicin—thyroid cancer	0.00103	0.00109	CcSEcCtD
Zuclopenthixol—Malaise—Doxorubicin—thyroid cancer	0.00102	0.00108	CcSEcCtD
Zuclopenthixol—Dry mouth—Epirubicin—thyroid cancer	0.00102	0.00108	CcSEcCtD
Zuclopenthixol—Vertigo—Doxorubicin—thyroid cancer	0.00102	0.00108	CcSEcCtD
Zuclopenthixol—Syncope—Doxorubicin—thyroid cancer	0.00101	0.00107	CcSEcCtD
Zuclopenthixol—Leukopenia—Doxorubicin—thyroid cancer	0.00101	0.00107	CcSEcCtD
Zuclopenthixol—Palpitations—Doxorubicin—thyroid cancer	0.000999	0.00106	CcSEcCtD
Zuclopenthixol—Anaphylactic shock—Epirubicin—thyroid cancer	0.000998	0.00106	CcSEcCtD
Zuclopenthixol—Loss of consciousness—Doxorubicin—thyroid cancer	0.000994	0.00105	CcSEcCtD
Zuclopenthixol—Shock—Epirubicin—thyroid cancer	0.000981	0.00104	CcSEcCtD
Zuclopenthixol—Convulsion—Doxorubicin—thyroid cancer	0.00098	0.00104	CcSEcCtD
Zuclopenthixol—Nervous system disorder—Epirubicin—thyroid cancer	0.000978	0.00104	CcSEcCtD
Zuclopenthixol—Thrombocytopenia—Epirubicin—thyroid cancer	0.000977	0.00103	CcSEcCtD
Zuclopenthixol—Hypertension—Doxorubicin—thyroid cancer	0.000976	0.00103	CcSEcCtD
Zuclopenthixol—Tachycardia—Epirubicin—thyroid cancer	0.000974	0.00103	CcSEcCtD
Zuclopenthixol—Skin disorder—Epirubicin—thyroid cancer	0.000969	0.00103	CcSEcCtD
Zuclopenthixol—Hyperhidrosis—Epirubicin—thyroid cancer	0.000964	0.00102	CcSEcCtD
Zuclopenthixol—Myalgia—Doxorubicin—thyroid cancer	0.000963	0.00102	CcSEcCtD
Zuclopenthixol—Anxiety—Doxorubicin—thyroid cancer	0.000959	0.00102	CcSEcCtD
Zuclopenthixol—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—thyroid cancer	0.000956	0.00101	CcSEcCtD
Zuclopenthixol—Discomfort—Doxorubicin—thyroid cancer	0.000951	0.00101	CcSEcCtD
Zuclopenthixol—Anorexia—Epirubicin—thyroid cancer	0.000951	0.00101	CcSEcCtD
Zuclopenthixol—Dry mouth—Doxorubicin—thyroid cancer	0.000942	0.000997	CcSEcCtD
Zuclopenthixol—Hypotension—Epirubicin—thyroid cancer	0.000932	0.000987	CcSEcCtD
Zuclopenthixol—Anaphylactic shock—Doxorubicin—thyroid cancer	0.000923	0.000977	CcSEcCtD
Zuclopenthixol—Musculoskeletal discomfort—Epirubicin—thyroid cancer	0.000909	0.000962	CcSEcCtD
Zuclopenthixol—Shock—Doxorubicin—thyroid cancer	0.000908	0.000961	CcSEcCtD
Zuclopenthixol—Nervous system disorder—Doxorubicin—thyroid cancer	0.000905	0.000958	CcSEcCtD
Zuclopenthixol—Thrombocytopenia—Doxorubicin—thyroid cancer	0.000904	0.000957	CcSEcCtD
Zuclopenthixol—Insomnia—Epirubicin—thyroid cancer	0.000902	0.000955	CcSEcCtD
Zuclopenthixol—Tachycardia—Doxorubicin—thyroid cancer	0.000901	0.000953	CcSEcCtD
Zuclopenthixol—Skin disorder—Doxorubicin—thyroid cancer	0.000897	0.000949	CcSEcCtD
Zuclopenthixol—Paraesthesia—Epirubicin—thyroid cancer	0.000896	0.000948	CcSEcCtD
Zuclopenthixol—Hyperhidrosis—Doxorubicin—thyroid cancer	0.000892	0.000944	CcSEcCtD
Zuclopenthixol—Dyspnoea—Epirubicin—thyroid cancer	0.000889	0.000941	CcSEcCtD
Zuclopenthixol—Somnolence—Epirubicin—thyroid cancer	0.000887	0.000939	CcSEcCtD
Zuclopenthixol—Anorexia—Doxorubicin—thyroid cancer	0.00088	0.000931	CcSEcCtD
Zuclopenthixol—Dyspepsia—Epirubicin—thyroid cancer	0.000878	0.000929	CcSEcCtD
Zuclopenthixol—Decreased appetite—Epirubicin—thyroid cancer	0.000867	0.000918	CcSEcCtD
Zuclopenthixol—Hypotension—Doxorubicin—thyroid cancer	0.000862	0.000913	CcSEcCtD
Zuclopenthixol—Gastrointestinal disorder—Epirubicin—thyroid cancer	0.000861	0.000912	CcSEcCtD
Zuclopenthixol—Fatigue—Epirubicin—thyroid cancer	0.00086	0.00091	CcSEcCtD
Zuclopenthixol—Pain—Epirubicin—thyroid cancer	0.000853	0.000903	CcSEcCtD
Zuclopenthixol—Constipation—Epirubicin—thyroid cancer	0.000853	0.000903	CcSEcCtD
Zuclopenthixol—Musculoskeletal discomfort—Doxorubicin—thyroid cancer	0.000841	0.00089	CcSEcCtD
Zuclopenthixol—Insomnia—Doxorubicin—thyroid cancer	0.000835	0.000884	CcSEcCtD
Zuclopenthixol—Paraesthesia—Doxorubicin—thyroid cancer	0.000829	0.000877	CcSEcCtD
Zuclopenthixol—Dyspnoea—Doxorubicin—thyroid cancer	0.000823	0.000871	CcSEcCtD
Zuclopenthixol—Feeling abnormal—Epirubicin—thyroid cancer	0.000822	0.00087	CcSEcCtD
Zuclopenthixol—Somnolence—Doxorubicin—thyroid cancer	0.000821	0.000869	CcSEcCtD
Zuclopenthixol—Gastrointestinal pain—Epirubicin—thyroid cancer	0.000816	0.000863	CcSEcCtD
Zuclopenthixol—Dyspepsia—Doxorubicin—thyroid cancer	0.000812	0.00086	CcSEcCtD
Zuclopenthixol—Decreased appetite—Doxorubicin—thyroid cancer	0.000802	0.000849	CcSEcCtD
Zuclopenthixol—Gastrointestinal disorder—Doxorubicin—thyroid cancer	0.000797	0.000843	CcSEcCtD
Zuclopenthixol—Fatigue—Doxorubicin—thyroid cancer	0.000796	0.000842	CcSEcCtD
Zuclopenthixol—Pain—Doxorubicin—thyroid cancer	0.000789	0.000835	CcSEcCtD
Zuclopenthixol—Constipation—Doxorubicin—thyroid cancer	0.000789	0.000835	CcSEcCtD
Zuclopenthixol—Abdominal pain—Epirubicin—thyroid cancer	0.000789	0.000835	CcSEcCtD
Zuclopenthixol—Body temperature increased—Epirubicin—thyroid cancer	0.000789	0.000835	CcSEcCtD
Zuclopenthixol—Feeling abnormal—Doxorubicin—thyroid cancer	0.000761	0.000805	CcSEcCtD
Zuclopenthixol—Gastrointestinal pain—Doxorubicin—thyroid cancer	0.000755	0.000799	CcSEcCtD
Zuclopenthixol—Hypersensitivity—Epirubicin—thyroid cancer	0.000735	0.000778	CcSEcCtD
Zuclopenthixol—Body temperature increased—Doxorubicin—thyroid cancer	0.00073	0.000772	CcSEcCtD
Zuclopenthixol—Abdominal pain—Doxorubicin—thyroid cancer	0.00073	0.000772	CcSEcCtD
Zuclopenthixol—Asthenia—Epirubicin—thyroid cancer	0.000716	0.000758	CcSEcCtD
Zuclopenthixol—Pruritus—Epirubicin—thyroid cancer	0.000706	0.000747	CcSEcCtD
Zuclopenthixol—Diarrhoea—Epirubicin—thyroid cancer	0.000683	0.000722	CcSEcCtD
Zuclopenthixol—Hypersensitivity—Doxorubicin—thyroid cancer	0.00068	0.00072	CcSEcCtD
Zuclopenthixol—Asthenia—Doxorubicin—thyroid cancer	0.000662	0.000701	CcSEcCtD
Zuclopenthixol—Dizziness—Epirubicin—thyroid cancer	0.00066	0.000698	CcSEcCtD
Zuclopenthixol—Pruritus—Doxorubicin—thyroid cancer	0.000653	0.000691	CcSEcCtD
Zuclopenthixol—Vomiting—Epirubicin—thyroid cancer	0.000634	0.000671	CcSEcCtD
Zuclopenthixol—Diarrhoea—Doxorubicin—thyroid cancer	0.000632	0.000668	CcSEcCtD
Zuclopenthixol—Rash—Epirubicin—thyroid cancer	0.000629	0.000666	CcSEcCtD
Zuclopenthixol—Dermatitis—Epirubicin—thyroid cancer	0.000628	0.000665	CcSEcCtD
Zuclopenthixol—Headache—Epirubicin—thyroid cancer	0.000625	0.000661	CcSEcCtD
Zuclopenthixol—Dizziness—Doxorubicin—thyroid cancer	0.00061	0.000646	CcSEcCtD
Zuclopenthixol—Nausea—Epirubicin—thyroid cancer	0.000593	0.000627	CcSEcCtD
Zuclopenthixol—Vomiting—Doxorubicin—thyroid cancer	0.000587	0.000621	CcSEcCtD
Zuclopenthixol—Rash—Doxorubicin—thyroid cancer	0.000582	0.000616	CcSEcCtD
Zuclopenthixol—Dermatitis—Doxorubicin—thyroid cancer	0.000581	0.000615	CcSEcCtD
Zuclopenthixol—Headache—Doxorubicin—thyroid cancer	0.000578	0.000612	CcSEcCtD
Zuclopenthixol—Nausea—Doxorubicin—thyroid cancer	0.000548	0.00058	CcSEcCtD
Zuclopenthixol—DRD1—Signaling by GPCR—CDK1—thyroid cancer	7.99e-05	0.00145	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling by GPCR—TSHR—thyroid cancer	7.97e-05	0.00144	CbGpPWpGaD
Zuclopenthixol—HTR6—Signaling Pathways—PRKAR1A—thyroid cancer	7.96e-05	0.00144	CbGpPWpGaD
Zuclopenthixol—CYP2D6—Metabolism—CHST14—thyroid cancer	7.92e-05	0.00143	CbGpPWpGaD
Zuclopenthixol—DRD5—Signaling Pathways—CALCA—thyroid cancer	7.84e-05	0.00142	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling by GPCR—PRKAR1A—thyroid cancer	7.84e-05	0.00142	CbGpPWpGaD
Zuclopenthixol—DRD2—GPCR downstream signaling—SST—thyroid cancer	7.62e-05	0.00138	CbGpPWpGaD
Zuclopenthixol—HTR6—Signaling Pathways—MEN1—thyroid cancer	7.6e-05	0.00138	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling by GPCR—PTCH1—thyroid cancer	7.57e-05	0.00137	CbGpPWpGaD
Zuclopenthixol—HTR2A—GPCR downstream signaling—SST—thyroid cancer	7.5e-05	0.00136	CbGpPWpGaD
Zuclopenthixol—HRH1—GPCR downstream signaling—SST—thyroid cancer	7.48e-05	0.00135	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling by GPCR—PTCH1—thyroid cancer	7.44e-05	0.00135	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling by GPCR—PTCH1—thyroid cancer	7.43e-05	0.00134	CbGpPWpGaD
Zuclopenthixol—HTR2A—Gastrin-CREB signalling pathway via PKC and MAPK—NRAS—thyroid cancer	7.35e-05	0.00133	CbGpPWpGaD
Zuclopenthixol—ADRA1A—GPCR downstream signaling—SST—thyroid cancer	7.34e-05	0.00133	CbGpPWpGaD
Zuclopenthixol—HRH1—Gastrin-CREB signalling pathway via PKC and MAPK—NRAS—thyroid cancer	7.34e-05	0.00133	CbGpPWpGaD
Zuclopenthixol—DRD2—GPCR downstream signaling—CALCA—thyroid cancer	7.33e-05	0.00133	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling by GPCR—PTCH1—thyroid cancer	7.29e-05	0.00132	CbGpPWpGaD
Zuclopenthixol—HTR2A—GPCR downstream signaling—CALCA—thyroid cancer	7.22e-05	0.00131	CbGpPWpGaD
Zuclopenthixol—HRH1—GPCR downstream signaling—CALCA—thyroid cancer	7.2e-05	0.0013	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Gastrin-CREB signalling pathway via PKC and MAPK—NRAS—thyroid cancer	7.2e-05	0.0013	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—TCF7L1—thyroid cancer	7.18e-05	0.0013	CbGpPWpGaD
Zuclopenthixol—DRD5—Signaling Pathways—CDK1—thyroid cancer	7.1e-05	0.00128	CbGpPWpGaD
Zuclopenthixol—ADRA1A—GPCR downstream signaling—CALCA—thyroid cancer	7.07e-05	0.00128	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—TCF7L1—thyroid cancer	7.07e-05	0.00128	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—TCF7L1—thyroid cancer	7.05e-05	0.00128	CbGpPWpGaD
Zuclopenthixol—DRD1—Signaling Pathways—TSHR—thyroid cancer	6.96e-05	0.00126	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling by GPCR—SST—thyroid cancer	6.92e-05	0.00125	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—TCF7L1—thyroid cancer	6.92e-05	0.00125	CbGpPWpGaD
Zuclopenthixol—HTR6—Signaling Pathways—PTCH1—thyroid cancer	6.88e-05	0.00124	CbGpPWpGaD
Zuclopenthixol—DRD1—Signaling Pathways—PRKAR1A—thyroid cancer	6.85e-05	0.00124	CbGpPWpGaD
Zuclopenthixol—ADRA2A—GPCR downstream signaling—SST—thyroid cancer	6.82e-05	0.00123	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling by GPCR—SST—thyroid cancer	6.81e-05	0.00123	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling by GPCR—SST—thyroid cancer	6.79e-05	0.00123	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling by GPCR—PTCH1—thyroid cancer	6.77e-05	0.00123	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling by GPCR—SST—thyroid cancer	6.67e-05	0.00121	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling by GPCR—CALCA—thyroid cancer	6.66e-05	0.00121	CbGpPWpGaD
Zuclopenthixol—ADRA2A—GPCR downstream signaling—CALCA—thyroid cancer	6.57e-05	0.00119	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling by GPCR—CALCA—thyroid cancer	6.55e-05	0.00119	CbGpPWpGaD
Zuclopenthixol—DRD1—Signaling Pathways—MEN1—thyroid cancer	6.55e-05	0.00118	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling by GPCR—CALCA—thyroid cancer	6.54e-05	0.00118	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—TCF7L1—thyroid cancer	6.43e-05	0.00116	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling by GPCR—CALCA—thyroid cancer	6.42e-05	0.00116	CbGpPWpGaD
Zuclopenthixol—CYP2D6—Metabolism—HPGD—thyroid cancer	6.38e-05	0.00116	CbGpPWpGaD
Zuclopenthixol—HTR2A—Gastrin-CREB signalling pathway via PKC and MAPK—KRAS—thyroid cancer	6.33e-05	0.00115	CbGpPWpGaD
Zuclopenthixol—HRH1—Gastrin-CREB signalling pathway via PKC and MAPK—KRAS—thyroid cancer	6.32e-05	0.00114	CbGpPWpGaD
Zuclopenthixol—HTR6—Signaling Pathways—SST—thyroid cancer	6.29e-05	0.00114	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Gastrin-CREB signalling pathway via PKC and MAPK—KRAS—thyroid cancer	6.2e-05	0.00112	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling by GPCR—SST—thyroid cancer	6.19e-05	0.00112	CbGpPWpGaD
Zuclopenthixol—HTR6—Signaling Pathways—CALCA—thyroid cancer	6.05e-05	0.0011	CbGpPWpGaD
Zuclopenthixol—DRD2—Circadian rythm related genes—TP53—thyroid cancer	6.03e-05	0.00109	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling by GPCR—CDK1—thyroid cancer	6.03e-05	0.00109	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling by GPCR—CALCA—thyroid cancer	5.96e-05	0.00108	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling by GPCR—CDK1—thyroid cancer	5.93e-05	0.00107	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling by GPCR—CDK1—thyroid cancer	5.92e-05	0.00107	CbGpPWpGaD
Zuclopenthixol—DRD1—Signaling Pathways—PTCH1—thyroid cancer	5.92e-05	0.00107	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling by GPCR—CDK1—thyroid cancer	5.81e-05	0.00105	CbGpPWpGaD
Zuclopenthixol—DRD5—Signaling Pathways—NRG1—thyroid cancer	5.7e-05	0.00103	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Metabolism—TPR—thyroid cancer	5.63e-05	0.00102	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Metabolism—PRKAR1A—thyroid cancer	5.54e-05	0.001	CbGpPWpGaD
Zuclopenthixol—HTR6—Signaling Pathways—CDK1—thyroid cancer	5.48e-05	0.000992	CbGpPWpGaD
Zuclopenthixol—DRD1—Signaling Pathways—SST—thyroid cancer	5.41e-05	0.00098	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling by GPCR—CDK1—thyroid cancer	5.4e-05	0.000977	CbGpPWpGaD
Zuclopenthixol—HTR2A—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—thyroid cancer	5.38e-05	0.000974	CbGpPWpGaD
Zuclopenthixol—HRH1—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—thyroid cancer	5.37e-05	0.000971	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—thyroid cancer	5.27e-05	0.000953	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—TSHR—thyroid cancer	5.26e-05	0.000951	CbGpPWpGaD
Zuclopenthixol—DRD1—Signaling Pathways—CALCA—thyroid cancer	5.21e-05	0.000943	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—TSHR—thyroid cancer	5.17e-05	0.000936	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—PRKAR1A—thyroid cancer	5.17e-05	0.000936	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—TSHR—thyroid cancer	5.16e-05	0.000934	CbGpPWpGaD
Zuclopenthixol—DRD5—Signaling Pathways—TERT—thyroid cancer	5.12e-05	0.000926	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—PRKAR1A—thyroid cancer	5.09e-05	0.000921	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—PRKAR1A—thyroid cancer	5.08e-05	0.000919	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—TSHR—thyroid cancer	5.06e-05	0.000916	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—PRKAR1A—thyroid cancer	4.98e-05	0.000902	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—MEN1—thyroid cancer	4.94e-05	0.000894	CbGpPWpGaD
Zuclopenthixol—DRD5—Signaling Pathways—HIF1A—thyroid cancer	4.89e-05	0.000886	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—MEN1—thyroid cancer	4.86e-05	0.00088	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—MEN1—thyroid cancer	4.85e-05	0.000878	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—MEN1—thyroid cancer	4.76e-05	0.000862	CbGpPWpGaD
Zuclopenthixol—DRD1—Signaling Pathways—CDK1—thyroid cancer	4.72e-05	0.000854	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—TSHR—thyroid cancer	4.71e-05	0.000851	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—PRKAR1A—thyroid cancer	4.63e-05	0.000838	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—PTCH1—thyroid cancer	4.47e-05	0.000809	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—MEN1—thyroid cancer	4.42e-05	0.000801	CbGpPWpGaD
Zuclopenthixol—HTR6—Signaling Pathways—NRG1—thyroid cancer	4.4e-05	0.000796	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—PTCH1—thyroid cancer	4.4e-05	0.000796	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—PTCH1—thyroid cancer	4.39e-05	0.000794	CbGpPWpGaD
Zuclopenthixol—DRD5—Signaling by GPCR—NRAS—thyroid cancer	4.31e-05	0.00078	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—PTCH1—thyroid cancer	4.31e-05	0.000779	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Platelet activation, signaling and aggregation—AKT1—thyroid cancer	4.23e-05	0.000765	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Metabolism—SLC5A5—thyroid cancer	4.21e-05	0.000762	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—SST—thyroid cancer	4.09e-05	0.00074	CbGpPWpGaD
Zuclopenthixol—DRD5—Signaling Pathways—BRAF—thyroid cancer	4.05e-05	0.000733	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—SST—thyroid cancer	4.02e-05	0.000728	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—SST—thyroid cancer	4.01e-05	0.000726	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—PTCH1—thyroid cancer	4e-05	0.000724	CbGpPWpGaD
Zuclopenthixol—HTR6—Signaling Pathways—TERT—thyroid cancer	3.95e-05	0.000715	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—SST—thyroid cancer	3.94e-05	0.000713	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—CALCA—thyroid cancer	3.93e-05	0.000712	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—CALCA—thyroid cancer	3.87e-05	0.000701	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—CALCA—thyroid cancer	3.86e-05	0.000699	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—CALCA—thyroid cancer	3.79e-05	0.000686	CbGpPWpGaD
Zuclopenthixol—DRD1—Signaling Pathways—NRG1—thyroid cancer	3.79e-05	0.000685	CbGpPWpGaD
Zuclopenthixol—HTR6—Signaling Pathways—HIF1A—thyroid cancer	3.78e-05	0.000684	CbGpPWpGaD
Zuclopenthixol—DRD5—Signaling by GPCR—KRAS—thyroid cancer	3.71e-05	0.000671	CbGpPWpGaD
Zuclopenthixol—CYP2D6—Metabolism—TPR—thyroid cancer	3.67e-05	0.000664	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—SST—thyroid cancer	3.66e-05	0.000662	CbGpPWpGaD
Zuclopenthixol—CYP2D6—Metabolism—PRKAR1A—thyroid cancer	3.61e-05	0.000653	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—CDK1—thyroid cancer	3.56e-05	0.000645	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Metabolism—RXRA—thyroid cancer	3.54e-05	0.00064	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—CALCA—thyroid cancer	3.52e-05	0.000637	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—CDK1—thyroid cancer	3.5e-05	0.000634	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—CDK1—thyroid cancer	3.5e-05	0.000633	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—CDK1—thyroid cancer	3.43e-05	0.000621	CbGpPWpGaD
Zuclopenthixol—DRD1—Signaling Pathways—TERT—thyroid cancer	3.4e-05	0.000615	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Hemostasis—NRAS—thyroid cancer	3.37e-05	0.00061	CbGpPWpGaD
Zuclopenthixol—HTR6—Signaling by GPCR—NRAS—thyroid cancer	3.33e-05	0.000602	CbGpPWpGaD
Zuclopenthixol—DRD1—Signaling Pathways—HIF1A—thyroid cancer	3.25e-05	0.000588	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—CDK1—thyroid cancer	3.19e-05	0.000577	CbGpPWpGaD
Zuclopenthixol—DRD5—Signaling by GPCR—HRAS—thyroid cancer	3.15e-05	0.000571	CbGpPWpGaD
Zuclopenthixol—HTR6—Signaling Pathways—BRAF—thyroid cancer	3.13e-05	0.000566	CbGpPWpGaD
Zuclopenthixol—DRD5—GPCR downstream signaling—AKT1—thyroid cancer	3.07e-05	0.000555	CbGpPWpGaD
Zuclopenthixol—DRD5—Signaling Pathways—CCND1—thyroid cancer	2.96e-05	0.000535	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Hemostasis—KRAS—thyroid cancer	2.9e-05	0.000525	CbGpPWpGaD
Zuclopenthixol—DRD1—Signaling by GPCR—NRAS—thyroid cancer	2.86e-05	0.000518	CbGpPWpGaD
Zuclopenthixol—HTR6—Signaling by GPCR—KRAS—thyroid cancer	2.86e-05	0.000518	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—NRG1—thyroid cancer	2.86e-05	0.000517	CbGpPWpGaD
Zuclopenthixol—DRD5—Signaling Pathways—PTEN—thyroid cancer	2.85e-05	0.000517	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—NRG1—thyroid cancer	2.81e-05	0.000509	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—NRG1—thyroid cancer	2.81e-05	0.000508	CbGpPWpGaD
Zuclopenthixol—DRD5—Signaling by GPCR—AKT1—thyroid cancer	2.78e-05	0.000504	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—NRG1—thyroid cancer	2.75e-05	0.000498	CbGpPWpGaD
Zuclopenthixol—CYP2D6—Metabolism—SLC5A5—thyroid cancer	2.74e-05	0.000497	CbGpPWpGaD
Zuclopenthixol—DRD1—Signaling Pathways—BRAF—thyroid cancer	2.69e-05	0.000487	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Hemostasis—TP53—thyroid cancer	2.58e-05	0.000467	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—TERT—thyroid cancer	2.57e-05	0.000465	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—NRG1—thyroid cancer	2.56e-05	0.000463	CbGpPWpGaD
Zuclopenthixol—DRD5—Signaling Pathways—NRAS—thyroid cancer	2.55e-05	0.000461	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—TERT—thyroid cancer	2.53e-05	0.000457	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—TERT—thyroid cancer	2.52e-05	0.000456	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—TERT—thyroid cancer	2.47e-05	0.000448	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Hemostasis—HRAS—thyroid cancer	2.47e-05	0.000447	CbGpPWpGaD
Zuclopenthixol—DRD1—Signaling by GPCR—KRAS—thyroid cancer	2.47e-05	0.000446	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—HIF1A—thyroid cancer	2.45e-05	0.000444	CbGpPWpGaD
Zuclopenthixol—HTR6—Signaling by GPCR—HRAS—thyroid cancer	2.43e-05	0.000441	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—HIF1A—thyroid cancer	2.42e-05	0.000437	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—HIF1A—thyroid cancer	2.41e-05	0.000436	CbGpPWpGaD
Zuclopenthixol—HTR6—GPCR downstream signaling—AKT1—thyroid cancer	2.37e-05	0.000428	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—HIF1A—thyroid cancer	2.37e-05	0.000428	CbGpPWpGaD
Zuclopenthixol—CYP2D6—Metabolism—RXRA—thyroid cancer	2.31e-05	0.000417	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—TERT—thyroid cancer	2.3e-05	0.000416	CbGpPWpGaD
Zuclopenthixol—HTR6—Signaling Pathways—CCND1—thyroid cancer	2.28e-05	0.000413	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Metabolism—PPARG—thyroid cancer	2.23e-05	0.000404	CbGpPWpGaD
Zuclopenthixol—HTR6—Signaling Pathways—PTEN—thyroid cancer	2.2e-05	0.000399	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—HIF1A—thyroid cancer	2.2e-05	0.000398	CbGpPWpGaD
Zuclopenthixol—DRD5—Signaling Pathways—KRAS—thyroid cancer	2.19e-05	0.000397	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Hemostasis—AKT1—thyroid cancer	2.18e-05	0.000394	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling by GPCR—NRAS—thyroid cancer	2.16e-05	0.000391	CbGpPWpGaD
Zuclopenthixol—HTR6—Signaling by GPCR—AKT1—thyroid cancer	2.15e-05	0.000389	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling by GPCR—NRAS—thyroid cancer	2.13e-05	0.000385	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling by GPCR—NRAS—thyroid cancer	2.12e-05	0.000384	CbGpPWpGaD
Zuclopenthixol—DRD1—Signaling by GPCR—HRAS—thyroid cancer	2.1e-05	0.000379	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling by GPCR—NRAS—thyroid cancer	2.08e-05	0.000377	CbGpPWpGaD
Zuclopenthixol—DRD1—GPCR downstream signaling—AKT1—thyroid cancer	2.04e-05	0.000369	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—BRAF—thyroid cancer	2.03e-05	0.000368	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—BRAF—thyroid cancer	2e-05	0.000362	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—BRAF—thyroid cancer	2e-05	0.000361	CbGpPWpGaD
Zuclopenthixol—HTR6—Signaling Pathways—NRAS—thyroid cancer	1.97e-05	0.000356	CbGpPWpGaD
Zuclopenthixol—DRD1—Signaling Pathways—CCND1—thyroid cancer	1.97e-05	0.000356	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—BRAF—thyroid cancer	1.96e-05	0.000354	CbGpPWpGaD
Zuclopenthixol—DRD5—Signaling Pathways—TP53—thyroid cancer	1.95e-05	0.000353	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling by GPCR—NRAS—thyroid cancer	1.94e-05	0.00035	CbGpPWpGaD
Zuclopenthixol—DRD1—Signaling Pathways—PTEN—thyroid cancer	1.9e-05	0.000343	CbGpPWpGaD
Zuclopenthixol—DRD5—Signaling Pathways—HRAS—thyroid cancer	1.86e-05	0.000337	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling by GPCR—KRAS—thyroid cancer	1.86e-05	0.000337	CbGpPWpGaD
Zuclopenthixol—DRD1—Signaling by GPCR—AKT1—thyroid cancer	1.85e-05	0.000335	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling by GPCR—KRAS—thyroid cancer	1.83e-05	0.000331	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling by GPCR—KRAS—thyroid cancer	1.83e-05	0.000331	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—BRAF—thyroid cancer	1.82e-05	0.000329	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling by GPCR—KRAS—thyroid cancer	1.79e-05	0.000325	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Metabolism—PTGS2—thyroid cancer	1.76e-05	0.000318	CbGpPWpGaD
Zuclopenthixol—DRD1—Signaling Pathways—NRAS—thyroid cancer	1.69e-05	0.000306	CbGpPWpGaD
Zuclopenthixol—HTR6—Signaling Pathways—KRAS—thyroid cancer	1.69e-05	0.000306	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling by GPCR—KRAS—thyroid cancer	1.67e-05	0.000302	CbGpPWpGaD
Zuclopenthixol—DRD5—Signaling Pathways—AKT1—thyroid cancer	1.65e-05	0.000298	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling by GPCR—HRAS—thyroid cancer	1.58e-05	0.000286	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling by GPCR—HRAS—thyroid cancer	1.56e-05	0.000282	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling by GPCR—HRAS—thyroid cancer	1.55e-05	0.000281	CbGpPWpGaD
Zuclopenthixol—DRD2—GPCR downstream signaling—AKT1—thyroid cancer	1.54e-05	0.000278	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Metabolism—PTEN—thyroid cancer	1.53e-05	0.000277	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling by GPCR—HRAS—thyroid cancer	1.52e-05	0.000276	CbGpPWpGaD
Zuclopenthixol—HTR2A—GPCR downstream signaling—AKT1—thyroid cancer	1.51e-05	0.000274	CbGpPWpGaD
Zuclopenthixol—HRH1—GPCR downstream signaling—AKT1—thyroid cancer	1.51e-05	0.000273	CbGpPWpGaD
Zuclopenthixol—HTR6—Signaling Pathways—TP53—thyroid cancer	1.5e-05	0.000272	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—CCND1—thyroid cancer	1.48e-05	0.000268	CbGpPWpGaD
Zuclopenthixol—ADRA1A—GPCR downstream signaling—AKT1—thyroid cancer	1.48e-05	0.000268	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—CCND1—thyroid cancer	1.46e-05	0.000264	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—CCND1—thyroid cancer	1.46e-05	0.000264	CbGpPWpGaD
Zuclopenthixol—DRD1—Signaling Pathways—KRAS—thyroid cancer	1.46e-05	0.000264	CbGpPWpGaD
Zuclopenthixol—CYP2D6—Metabolism—PPARG—thyroid cancer	1.46e-05	0.000264	CbGpPWpGaD
Zuclopenthixol—HTR6—Signaling Pathways—HRAS—thyroid cancer	1.44e-05	0.00026	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—PTEN—thyroid cancer	1.43e-05	0.000259	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—CCND1—thyroid cancer	1.43e-05	0.000259	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling by GPCR—HRAS—thyroid cancer	1.42e-05	0.000256	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—PTEN—thyroid cancer	1.41e-05	0.000255	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—PTEN—thyroid cancer	1.41e-05	0.000254	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling by GPCR—AKT1—thyroid cancer	1.4e-05	0.000253	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—PTEN—thyroid cancer	1.38e-05	0.00025	CbGpPWpGaD
Zuclopenthixol—ADRA2A—GPCR downstream signaling—AKT1—thyroid cancer	1.38e-05	0.000249	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling by GPCR—AKT1—thyroid cancer	1.37e-05	0.000249	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling by GPCR—AKT1—thyroid cancer	1.37e-05	0.000248	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling by GPCR—AKT1—thyroid cancer	1.35e-05	0.000244	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—CCND1—thyroid cancer	1.33e-05	0.00024	CbGpPWpGaD
Zuclopenthixol—DRD1—Signaling Pathways—TP53—thyroid cancer	1.29e-05	0.000234	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—PTEN—thyroid cancer	1.28e-05	0.000232	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—NRAS—thyroid cancer	1.28e-05	0.000231	CbGpPWpGaD
Zuclopenthixol—HTR6—Signaling Pathways—AKT1—thyroid cancer	1.27e-05	0.00023	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—NRAS—thyroid cancer	1.26e-05	0.000227	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—NRAS—thyroid cancer	1.25e-05	0.000227	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling by GPCR—AKT1—thyroid cancer	1.25e-05	0.000226	CbGpPWpGaD
Zuclopenthixol—DRD1—Signaling Pathways—HRAS—thyroid cancer	1.24e-05	0.000224	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—NRAS—thyroid cancer	1.23e-05	0.000223	CbGpPWpGaD
Zuclopenthixol—CYP2D6—Metabolism—PTGS2—thyroid cancer	1.15e-05	0.000207	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—NRAS—thyroid cancer	1.14e-05	0.000207	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—KRAS—thyroid cancer	1.1e-05	0.000199	CbGpPWpGaD
Zuclopenthixol—DRD1—Signaling Pathways—AKT1—thyroid cancer	1.09e-05	0.000198	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—KRAS—thyroid cancer	1.08e-05	0.000196	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—KRAS—thyroid cancer	1.08e-05	0.000195	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—KRAS—thyroid cancer	1.06e-05	0.000192	CbGpPWpGaD
Zuclopenthixol—CYP2D6—Metabolism—PTEN—thyroid cancer	9.99e-06	0.000181	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—KRAS—thyroid cancer	9.84e-06	0.000178	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—TP53—thyroid cancer	9.77e-06	0.000177	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—TP53—thyroid cancer	9.62e-06	0.000174	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—TP53—thyroid cancer	9.6e-06	0.000174	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—TP53—thyroid cancer	9.42e-06	0.00017	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—HRAS—thyroid cancer	9.35e-06	0.000169	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—HRAS—thyroid cancer	9.2e-06	0.000166	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—HRAS—thyroid cancer	9.18e-06	0.000166	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—HRAS—thyroid cancer	9e-06	0.000163	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Metabolism—AKT1—thyroid cancer	8.84e-06	0.00016	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—TP53—thyroid cancer	8.75e-06	0.000158	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—HRAS—thyroid cancer	8.37e-06	0.000151	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—AKT1—thyroid cancer	8.25e-06	0.000149	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—AKT1—thyroid cancer	8.12e-06	0.000147	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—AKT1—thyroid cancer	8.1e-06	0.000147	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—AKT1—thyroid cancer	7.95e-06	0.000144	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—AKT1—thyroid cancer	7.39e-06	0.000134	CbGpPWpGaD
Zuclopenthixol—CYP2D6—Metabolism—AKT1—thyroid cancer	5.76e-06	0.000104	CbGpPWpGaD
